IGNY Ignyte Acquisition Corp.

Ignyte Acquisition Corp.

Consumer Electronics/Appliances

Industrials

Ignyte Acquisition Corp. does not have significant operations. It intends to effect a merger, stock exchange, asset acquisition, stock purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.

IPO Year: 2021

Exchange: NASDAQ

Website: ignytespac.com

Recent Analyst Ratings for Ignyte Acquisition Corp.

Date	Price Target	Rating	Analyst

See more ratings

Ignyte Acquisition Corp. Press Releases

Fastest customizable press release news feed in the world

View All

Peak Bio Co., Ltd. to List on NASDAQ Following Successful Business Combination with Ignyte Acquisition Corp.

Combined Company Scheduled to Commence Trading on NASDAQ Under the Ticker Symbol "PKBO" Peak Bio Co., Ltd. ("Peak Bio"), a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory diseases, today announced the completion of its business combination (the "Business Combination") with Ignyte Acquisition Corp. (NASDAQ:IGNY) ("Ignyte"), a special purpose acquisition company. The transaction was approved at a special meeting of Ignyte's stockholders held on October 25, 2022 (the "Special Meeting"). Ignyte's stockholders also voted to approve all other proposals presented at the Special Meeting. Ignyte's Board of Direct

11/2/22 7:30:00 AM ET

$IGNY

Consumer Electronics/Appliances

Industrials

Ignyte Acquisition Corp. Stockholders Approve Proposed Business Combination with Peak Bio

Transaction Expected to Close on October 31, 2022 Ignyte Acquisition Corp. ("Ignyte") (NASDAQ:IGNY), a publicly traded special purpose acquisition company, today announced that Ignyte's stockholders have approved its proposed business combination (the "Business Combination") with Peak Bio Co., Ltd. ("Peak Bio") at a Special Meeting of its stockholders held on October 25, 2022 (the "Special Meeting"). The Special Meeting to be held on October 31, 2022 has been canceled. Approximately 75% of the votes cast at the Special Meeting, representing approximately 75% of Ignyte's outstanding shares of common stock entitled to vote at the Special Meeting, were cast in favor of the proposal to approv

10/27/22 8:05:00 AM ET

$IGNY

Consumer Electronics/Appliances

Industrials

Peak Bio and Ignyte Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Oncology and Inflammation Company

- Company to be led by Hoyoung Huh, M.D. Ph.D., serial entrepreneur / investor with notable public and private biotech board positions - $25 million private investment in public equity ("PIPE") with participation from leading healthcare institutional investor, Palo Alto Investors (PAI) with additional participation from Peak Bio's CEO, Hoyoung Huh, MD, Ph.D. - Differentiated pipeline includes next generation Neutrophil Elastase Inhibitor targeting AATD / ARDS and robust preclinical ADC oncology platform utilizing Antibody Drug Conjugates - Anticipated cash at closing expected to fully fund the company through 2024 allowing for multiple milestones in ADC program and interim Phase II for A

4/28/22 4:32:00 PM ET

$IGNY

Consumer Electronics/Appliances

Industrials

Ignyte Acquisition Corp. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

Ignyte Acquisition Corp. (NASDAQ:IGNYU) (the "Company") today announced that on May 28, 2021 it received a notice from Nasdaq Regulation indicating that, as a result of not having timely filed its Quarterly Report on Form 10-Q for the period ended March 31, 2021 (the "Form 10-Q"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). The Nasdaq notice has no immediate effect on the listing or trading of the Company's units, Class A ordinary shares or warrants on the Nasdaq Capital Market. The Notice provides that the Company must submit a plan to

6/1/21 2:11:00 PM ET

$IGNY

Consumer Electronics/Appliances

Industrials

Ignyte Acquisition Corp.

Recent Analyst Ratings for Ignyte Acquisition Corp.

Ignyte Acquisition Corp.

Recent Analyst Ratings for Ignyte Acquisition Corp.

Ignyte Acquisition Corp. Insider Trading

Lamond Stephen J bought 5,600 shares, increasing direct ownership by 39% to 19,850 units (SEC Form 4)

Lamond Stephen J bought 14,250 shares (SEC Form 4) (Amendment)

SEC Form 4: Huh Hoyoung bought 45,000 shares, increasing direct ownership by 0.54% to 8,382,742 units

SEC Form 4: Huh Hoyoung bought 80,000 shares, increasing direct ownership by 0.97% to 8,337,742 units

SEC Form 4: Lamond Stephen J bought 28,500 shares

SEC Form 4: Huh Hoyoung bought 25,000 shares, increasing direct ownership by 0.30% to 8,257,742 units

SEC Form 4: Huh Hoyoung bought 50,000 shares, increasing direct ownership by 0.61% to 8,232,742 units

SEC Form 4: Huh Hoyoung bought 47,000 shares, increasing direct ownership by 0.58% to 8,182,742 units

SEC Form 4: Huh Hoyoung bought 0 shares (Amendment)

SEC Form 3: New insider Friedman Michael R. claimed ownership of 18,692 shares and claimed ownership of 35,000 units of Warrant

Ignyte Acquisition Corp. Insider Purchases

Lamond Stephen J bought 5,600 shares, increasing direct ownership by 39% to 19,850 units (SEC Form 4)

Lamond Stephen J bought 14,250 shares (SEC Form 4) (Amendment)

SEC Form 4: Huh Hoyoung bought 45,000 shares, increasing direct ownership by 0.54% to 8,382,742 units

SEC Form 4: Huh Hoyoung bought 80,000 shares, increasing direct ownership by 0.97% to 8,337,742 units

SEC Form 4: Lamond Stephen J bought 28,500 shares

SEC Form 4: Huh Hoyoung bought 25,000 shares, increasing direct ownership by 0.30% to 8,257,742 units

Ignyte Acquisition Corp. Press Releases

Peak Bio Co., Ltd. to List on NASDAQ Following Successful Business Combination with Ignyte Acquisition Corp.

Ignyte Acquisition Corp. Stockholders Approve Proposed Business Combination with Peak Bio

Peak Bio and Ignyte Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Oncology and Inflammation Company

Ignyte Acquisition Corp. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

Ignyte Acquisition Corp. SEC Filings

SEC Form 8-K filed by Ignyte Acquisition Corp.

SEC Form 8-K filed by Ignyte Acquisition Corp.

Ignyte Acquisition Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities

Ignyte Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

SEC Form NT 10-Q filed by Ignyte Acquisition Corp.

SEC Form 8-K filed by Ignyte Acquisition Corp.

Ignyte Acquisition Corp. filed SEC Form 8-K: Leadership Update

SEC Form 10-Q filed by Ignyte Acquisition Corp.

Ignyte Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

SEC Form NT 10-Q filed by Ignyte Acquisition Corp.

Ignyte Acquisition Corp. Financials

Peak Bio and Ignyte Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Oncology and Inflammation Company

Ignyte Acquisition Corp. Large Ownership Changes

SEC Form SC 13D filed by Ignyte Acquisition Corp.

SEC Form SC 13G filed by Ignyte Acquisition Corp.

SEC Form SC 13G/A filed by Ignyte Acquisition Corp. (Amendment)

SEC Form SC 13G/A filed by Ignyte Acquisition Corp. (Amendment)

SEC Form SC 13G/A filed by Ignyte Acquisition Corp. (Amendment)

SEC Form SC 13G filed by Ignyte Acquisition Corp.

SEC Form SC 13G/A filed by Ignyte Acquisition Corp. (Amendment)

SEC Form SC 13G filed by Ignyte Acquisition Corp.

SEC Form SC 13G/A filed by Ignyte Acquisition Corp. (Amendment)

SEC Form SC 13G/A filed by Ignyte Acquisition Corp. (Amendment)